{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T17:05:29Z","timestamp":1765040729908},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jpba.2017.11.035","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T05:01:06Z","timestamp":1511154066000},"page":"475-481","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3\u00df-glucuronide and morphine-6\u00df-glucuronide in human plasma"],"prefix":"10.1016","volume":"149","author":[{"given":"Peter","family":"de Bruijn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelien J.M.","family":"Kuip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Ho","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stijn L.W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2017.11.035_bib0005","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdm056","article-title":"Prevalence of pain in patients with cancer: a systematic review of the past 40 years","volume":"18","author":"van den Beuken-van Everdingen","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jpba.2017.11.035_bib0010","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1200\/JCO.2001.19.9.2542","article-title":"Strategies to manage the adverse effects of oral morphine: an evidence-based report","volume":"19","author":"Cherny","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2017.11.035_bib0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00520-005-0843-2","article-title":"No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients","volume":"14","author":"Riley","year":"2006","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.jpba.2017.11.035_bib0020","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bcp.13129","article-title":"A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients","volume":"83","author":"Kuip","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2017.11.035_bib0025","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2217\/pgs-2016-0082","article-title":"Opioid treatment failure in cancer patients: the role of clinical and genetic factors","volume":"17","author":"Oosten","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jpba.2017.11.035_bib0030","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/jps.2600660921","article-title":"Isolation and identification of morphine 3- and 6-glucuronides, morphine 3,6-diglucuronide, morphine 3-ethereal sulfate, normorphine, and normorphine 6-glucuronide as morphine metabolites in humans","volume":"66","author":"Yeh","year":"1977","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2017.11.035_bib0035","first-page":"344","article-title":"Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations","volume":"24","author":"Hasselstrom","year":"1993","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2017.11.035_bib0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5055\/jom.2005.0021","article-title":"Morphine analgesia in cancer pain: role of the glucuronides","volume":"1","author":"Penson","year":"2005","journal-title":"J. Opioid Manag."},{"key":"10.1016\/j.jpba.2017.11.035_bib0045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.1993.127","article-title":"The pharmacokinetics of morphine and morphine glucuronides in kidney failure","volume":"54","author":"Osborne","year":"1993","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2017.11.035_bib0050","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S0140-6736(88)91691-1","article-title":"Analgesic activity of morphine-6-glucuronide","volume":"1","author":"Osborne","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2017.11.035_bib0055","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0304-3959(95)00180-8","article-title":"Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain","volume":"64","author":"Donner","year":"1996","journal-title":"Pain"},{"key":"10.1016\/j.jpba.2017.11.035_bib0060","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1089\/jpm.2007.0200","article-title":"Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature","volume":"11","author":"Tassinari","year":"2008","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.jpba.2017.11.035_bib0065","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jpainsymman.2009.06.001","article-title":"Opioid rotation: the science and the limitations of the equianalgesic dose table","volume":"38","author":"Knotkova","year":"2009","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.jpba.2017.11.035_bib0070","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1200\/JCO.2002.20.1.348","article-title":"Opioid rotation in the management of refractory cancer pain","volume":"20","author":"Indelicato","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2017.11.035_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2015.06.028","article-title":"Development of a new multi-analyte assay for the simultaneous detection of opioids in serum and other body fluids using liquid chromatography-tandem mass spectrometry","volume":"1001","author":"Eckart","year":"2015","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2017.11.035_bib0080","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/jms.1021","article-title":"An automated and fully validated LC-MS\/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites","volume":"41","author":"Musshoff","year":"2006","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jpba.2017.11.035_bib0085","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00228-015-2005-x","article-title":"Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients","volume":"72","author":"Oosten","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2017.11.035_bib0090","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/dta.1778","article-title":"Quantitative determination of fentanyl in newborn pig plasma and cerebrospinal fluid samples by HPLC\u2013MS\/MS","volume":"7","author":"Blanco","year":"2015","journal-title":"Drug Test Anal."},{"issue":"4","key":"10.1016\/j.jpba.2017.11.035_bib0095","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1345\/aph.18003","article-title":"Domperidone: a peripherally acting dopamine2-receptor antagonist","volume":"33","author":"Barone","year":"1999","journal-title":"Ann. Pharmacother."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708517322549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708517322549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T08:16:19Z","timestamp":1536308179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708517322549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":19,"alternative-id":["S0731708517322549"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2017.11.035","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3\u00df-glucuronide and morphine-6\u00df-glucuronide in human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2017.11.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}